Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report
IJU Case Reports · 2026-07 · 9 (4)
DOI: 10.1002/iju5.70204 ↗Kurz gefasst
Fallbericht in der Zeitschrift IJU Case Reports, online erschienen am 01.06.2026. Verfasst von Sho Shimasaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC. Case Presentation A 71‐year‐old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC (pT1b). Six months later, computed tomography (CT) and 18 F‐fluorodeoxyglucose positron emission tomography (PET)/CT revealed lung, bone, and adrenal metastases. Bone biopsy confirmed metastatic MTSCC, and the patient was classified as poor risk. Combination therapy with nivolumab and ipilimumab was initiated. After two cycles, PET/CT showed marked regression of metastatic lesions (SUV max decreased from 21.7 to 4.3). RECIST evaluation demonstrated a partial response. Genomic profiling revealed microsatellite stability and a low tumor mutational burden, with no clinically actionable alterations identified on FoundationOne CDx. No disease progression was observed at 9 months.
Conclusion
This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
- Department of Diagnostic Pathology Kochi Medical School, Kochi University Nankoku Kochi Japan.
- Department of Urology Chikamori Hospital Kochi Kochi Japan.
- Department of Urology Kochi Prefectural Aki General Hospital Aki Kochi Japan.
ORCID-Profile: Shinkuro Yamamoto
Zitieren
APA
Shimasaki, S., Yamamoto, S., Iguchi, M., Yamashita, E., Atagi, K., Shiba, Y., Fukata, S., Satake, H., Karashima, T., & Inoue, K. (2026). Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. IJU Case Reports, 9(4). https://doi.org/10.1002/iju5.70204
Vancouver
Shimasaki S, Yamamoto S, Iguchi M, Yamashita E, Atagi K, Shiba Y, et al. Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. IJU Case Reports. 2026;9(4). doi:10.1002/iju5.70204
BibTeX
@article{Shimasaki2026,
author = {Shimasaki, Sho and Yamamoto, Shinkuro and Iguchi, Mitsuko and Yamashita, Erika and Atagi, Kaya and Shiba, Yuhei and Fukata, Satoshi and Satake, Hirofumi and Karashima, Takashi and Inoue, Keiji},
title = {Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report},
journal = {IJU Case Reports},
year = {2026},
volume = {9},
number = {4},
doi = {10.1002/iju5.70204}
}
EUVIMED